p. 70 p. 94 p. 102 p. 105 p. 108

Transcription

1 European League Against Rheumatism EULAR - a vehicle for communication p. 3 EULAR - a vehicle for communication; the role of ILAR p. 8 Overview on the Scientific Basis of Rheumatic Diseases Molecular and cellular basis of rheumatoid joint destruction p. 15 Euphenic prevention of rheumatoid arthritis p. 20 Molecular concepts in the approach to therapy p. 25 Sjogren's syndrome. The crossroads of autoimmunity and lymphoid malignancy p. 31 Quo vadis, pediatric rheumatology? p. 36 The spondylarthropathies p. 41 Chlamydia-induced arthritis. Clinical features, diagnosis and therapy p. 49 Update on osteoporosis p. 63 The patient, her disease, and her environment. How to make life easier for the rheumatic patient Immunological and Biochemical Background of Inflammation, Cartilage Damage and Joint Destruction Immunological mechanisms p. 70 T-cell subsets in rheumatoid arthritis p. 79 CD5-carrying B-cells in rheumatoid arthritis p. 82 Purification of 205-kDa synovial protein stimulatory for T cells p. 85 Molecular development of the B-cell repertoire in systemic autoimmunity p. 91 IgM rheumatoid factors in rheumatoid inflammation: no apparent restriction in germline immunoglobulin and relatively little somatic mutation p. 94 Are HLA-B27-positive individuals immunologically unique? p. 98 Experimental arthritis models have revealed the critical significance of immunity to the 65-kDa heat shock protein in human arthritic diseases Elicitation and modulation of autoimmune reactions to cartilage-derived collagen II in experimental and human arthritis Progressive polyarthritis and ankylosing spondylitis produced by proteoglycan antigens in Balb/c mice p. 102 p. 105 p. 108 Mast cells and histopathology of the rheumatoid lesion p. 112 Mediators of inflammation TNF[alpha] and TNF receptor expression and regulation in rheumatoid arthritis p. 115 The contribution of elevated intra-articular pressure to the pathogenesis of chronic synovitis p. 118 Lipoxygenase products in inflammatory joint disease p. 124 Neural influences in musculoskeletal diseases p. 127 Neuropeptides in joint inflammation p. 132 Neuroendocrine changes in inflammatory arthritis p. 135 Neurogenic inflammation, capsaicin and counterirritation p. 137 Processing of nociceptive information in the central nervous system of rats with joint-inflamed induced hyperalgesia p. 141 Substance P in rheumatic diseases: clinical implication p. 144 Sex hormones and rheumatic diseases p. 148

2 Trace elements and vitamin E in rheumatoid arthritis (RA), inflammation vs. diet p. 153 Cartilage damage The role of cartilage proteoglycans in the pathogenesis of arthritis p. 157 Synovial fluid and serum markers of cartilage degradation in human arthritis p. 161 Animal models in osteoarthritis research p. 163 Type II collagen gene mutations in familial osteoarthritis (OA) p. 165 Biochemical factors in osteoarthritis p. 168 Biochemical backgrounds of joint destruction in osteoarthrosis p. 171 Do cytokines play a role in the joint destruction in osteoarthrosis? p. 175 Effects of NSAIDs on cartilage proteoglycan and synovial prostaglandin metabolism in relation to progression of joint deterioration in osteoarthritis p. 177 The effects of NSAIDs on the course of osteoarthritis p. 184 Osteophytosis: radiographic perspective p. 189 What is an osteophyte? p. 192 Why do osteophytes form? p. 195 Osteophytes and other bone changes in osteoarthrosis p. 198 Osteophytes and 'enthesophytes' of the knee joint: differences and similarities p. 202 Hormonal and metabolic effects on osteophyte formation p. 206 Treatment of osteophytes. Necessary or not? p. 209 MR of the hip with emphasis on avascular necrosis p. 211 MR imaging of the hand and wrist p. 215 Clinical Spectrum of Rheumatic Diseases Autoimmune diseases Subgroups and symptom clusters in autoimmune diseases p. 219 Overlap of the polysystemic autoimmune diseases p. 222 Subgroups and symptom clusters in autoimmune diseases p. 225 Serological markers of clinical subsets in connective tissue diseases p. 230 Adult and juvenile rheumatoid arthritis Mortality in rheumatoid arthritis: prediction by poor clinical status p. 234 Progression in rheumatoid arthritis p. 238 Generalized secondary amyloidosis in rheumatoid arthritis p. 241 Bone and joint oddities mimicking juvenile chronic arthritis p. 245 Prognostic factors in juvenile arthritis complicated with amyloidosis p. 247 Enthesopathies Enthesitis and tendon inflammation. What type of rheumatic disease? p. 250 Enthesopathy: the common pathologic hallmark of seronegative spondyloarthropathies (SNSA) p. 251 Enthesitis and tendinitis in ankylosing spondylitis p. 254 Possible interaction between the infectious agents and the host in some rheumatic disorders p. 259 T-cell responses in reactive arthritis p. 263 Juvenile reactive arthritis (JREA) nosologic lines and diagnostic problems p. 266

3 Infection and arthritis Arthritis and HIV infection p. 269 Treatment of Lyme arthritis p. 272 Lequesne's questionnaire (LQ) in the assessment of knee osteoarthritis (OA) severity p. 275 Epidemiology of osteoporosis p. 278 Prevention and treatment of osteoporosis p. 282 Fibromyalgia and soft tissue rheumatism Does fibromyalgia exist? p. 284 Fibromyalgia: a neuroendocrinologic disease? p. 287 Mechanical hyperalgesia in tennis elbow p. 290 Non-pharmaceutical treatment of fibromyalgia: influence on quality of life p. 293 Advances in Therapeutic Modalities in Rheumatology Disease-modifying antirheumatic drugs The controlled clinical trial: the gold standard with feet of clay p. 299 Outcome methods for evaluating DMARD efficacy in rheumatoid arthritis p. 302 Assessing function in clinical trials p. 304 Safety and toxicity of disease-modifying antirheumatic drugs p. 306 Slow-acting drugs do not effect the outcome of rheumatoid arthritis p. 309 DMARDs: do they retard progression of radiological joint damage in rheumatoid arthritis? p. 312 Early DMARD treatment of rheumatoid arthritis p. 316 T-cell vaccination in rheumatoid arthritis p. 318 Cyclosporin in rheumatoid arthritis p. 320 Systemic and topical NSAIDs The relative toxicity of non-steroidal anti-inflammatory drugs (NSAIDs) p. 322 Tolerance of NSAIDs: pseudo-allergic and allergic reactions p. 325 Topical NSAIDs p. 328 Significance of topical NSAIDs in the context of overall treatment methods in rheumatic disease p. 330 Pharmacokinetic studies of topical NSAIDs p. 333 Topical therapy as alternative treatment of osteoarthritis p. 336 Intraarticular therapy European experience with intra-articular corticoid therapy p. 341 Radiosynoviorthesis p. 344 Intra-articular therapy: chemical synoviorthesis with natriummorrhuat (Varicocid) and other substances Surgical therapy p. 349 Experiences in hip endoprosthetics with special reference to rheumatoid arthritis p. 352 The Butel iso-elastic hip prosthesis p. 354 Operative intervention in rheumatoid arthritic knee p. 355

4 EULAR knee arthroplasty assessment project - results with cemented total condylar prostheses p. 357 A comparative study of two different knee systems in the same patient p. 359 Cementless total knee replacement arthroplasty in inflammatory diseases with special reference to AGC p. 365 The present status of total elbow replacement p. 372 Implants in the hand in rheumatoid arthritis p. 375 Surgery in ankylosing spondylitis p. 378 Physiotherapy in rheumatology Controlled trials in physiotherapy - a Hungarian approach p. 382 Effects of physical applications on experimental models of inflammation p. 384 Hydrotherapy and balneotherapy: State of the art p. 390 Kinesitherapy in the treatment of rheumatic diseases p. 393 The most effective rehabilitation medicine: home treatment in some of the common rheumatological conditions - a controlled study Social Aspects, Teamwork and Education in Rheumatology Social aspects p. 397 Science and the patient p. 403 Significant life events (LE): do they modify the short- and medium-term course of rheumatoid arthritis (RA)? p. 404 Barbara and her juvenile chronic arthritis: a doctor's story p. 408 My own story about a life with juvenile chronic arthritis (JCA) p. 410 Surgery and ankylosing spondylitis p. 414 Teamwork Specialization and collaboration in the treatment of rheumatoid arthritis patients p. 417 Arthritis care at the district level p. 420 Improvement of nearby domicile care for patients suffering from rheumatism by the German League Against Rheumatism (GLAR) - report on a model implemented by the Schleswig-Holstein branch of the GLAR p. 423 The rheumatoid arthritis school - a form of teamwork p. 427 The role of the pharmacist in the rheumatology health-care team p. 429 Effects of group counselling for rheumatoid arthritis patients on measures of psychological adjustment to illness Contributions by self-help groups to the quality of life within a society in transformation Education in rheumatology p. 432 p. 436 EULAR/WHO guidelines for an undergraduate program in rheumatology p. 438 European exchange in postgraduate education in rheumatology p. 441 Cooperation between pharmaceutical companies and physicians to improve the medical care of rheumatic patients in daily clinical practice p. 443 ILAR resource center for educational material p. 446 EURORITS program of study visits for young rheumatologists p. 448 Postgraduate rheumatology education in Europe - report of a questionnaire survey p. 450 Postgraduate courses on rheumatology for nursing staff p. 453

5 Index of authors p. 457 Table of Contents provided by Blackwell's Book Services and R.R. Bowker. Used with permission.